These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 31097390)
21. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Shah D; Shrestha R; Ramlal R; Hatton J; Saeed H Ann Oncol; 2017 Jun; 28(6):1403. PubMed ID: 28368439 [No Abstract] [Full Text] [Related]
22. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab. Venkatesh S; Al-Haseni A; Sahni D BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718 [TBL] [Abstract][Full Text] [Related]
23. Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Haque S; Yellu M; Randhawa J; Hashemi-Sadraei N Drug Des Devel Ther; 2017; 11():2537-2549. PubMed ID: 28919706 [TBL] [Abstract][Full Text] [Related]
24. Pembrolizumab for the treatment of gastric cancer. Kamath SD; Kalyan A; Benson AB Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940 [TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Tripathi A; Plimack ER Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502 [TBL] [Abstract][Full Text] [Related]
26. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Reimer A; Lu S; He Y; Bruckner-Tuderman L; Technau-Hafsi K; Meiss F; Has C; von Bubnoff D J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):e1-e3. PubMed ID: 31374134 [No Abstract] [Full Text] [Related]
27. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States. Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699 [TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab as a first-line therapy in spinocellular esophageal cancer. Křížová L; Charvát F; Petruželka L Klin Onkol; 2021; 34(1):59-61. PubMed ID: 33657821 [TBL] [Abstract][Full Text] [Related]
29. The Future of Front-line Metastatic Bladder Cancer is Platinum-free. Young M Eur Urol Focus; 2024 Mar; 10(2):215-216. PubMed ID: 38658299 [TBL] [Abstract][Full Text] [Related]
30. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Liu RC; Consuegra G; Chou S; Fernandez Peñas P Clin Exp Dermatol; 2019 Aug; 44(6):643-646. PubMed ID: 30618056 [TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer. Ueki Y; Suzuki M; Horikawa Y; Watanabe H; Yamaguchi Y; Morita C; Tsukada A; Takumida H; Kusaba Y; Katsuno T; Tsujimoto Y; Sakamoto K; Hashimoto M; Terada J; Ishii S; Takasaki J; Naka G; Iikura M; Izumi S; Takeda Y; Hojo M; Sugiyama H Thorac Cancer; 2020 Sep; 11(9):2731-2735. PubMed ID: 32767641 [TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265 [TBL] [Abstract][Full Text] [Related]
33. Complete Response to Immunotherapy Using Pembrolizumab in a Patient With Conjunctival Squamous Cell Carcinoma With Nodal Metastasis. Fan J; Goldberg H; Torres-Cabala CA; Stewart J; Nagarajan P; Debnam M; Crouse EC; Lu T; Ferrarotto R; Esmaeli B Ophthalmic Plast Reconstr Surg; 2024 Sep-Oct 01; 40(5):e171-e174. PubMed ID: 38687306 [TBL] [Abstract][Full Text] [Related]
34. [An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function]. Sazuka M; Murano Y; Takada K; Nonaka K; Yamada H; Yamamoto H Nihon Ronen Igakkai Zasshi; 2018; 55(4):679-685. PubMed ID: 30542036 [TBL] [Abstract][Full Text] [Related]
35. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226 [TBL] [Abstract][Full Text] [Related]
36. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403 [TBL] [Abstract][Full Text] [Related]
37. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer]. Yonenobu Y; Ishijima M; Toyooka K; Fujimura H Rinsho Shinkeigaku; 2019 Feb; 59(2):105-108. PubMed ID: 30700688 [TBL] [Abstract][Full Text] [Related]
38. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report. Hunter L; Moser J; Sturge C; Barraza G; Colonna S J Oncol Pharm Pract; 2020 Jan; 26(1):216-219. PubMed ID: 30832555 [TBL] [Abstract][Full Text] [Related]
39. Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer. Garje R; Chau JJ; Chung J; Wanat K; Zakharia Y J Immunother; 2018 Jan; 41(1):42-44. PubMed ID: 29111983 [TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer? Ravulapati S; Leung C; Poddar N; Tu Y Am J Med; 2017 May; 130(5):e207-e208. PubMed ID: 28249663 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]